These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 21854869)

  • 1. The emerging role of nuclear factor kappa B in renal cell carcinoma.
    Morais C; Gobe G; Johnson DW; Healy H
    Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
    Qi H; Ohh M
    Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.
    An J; Fisher M; Rettig MB
    Oncogene; 2005 Feb; 24(9):1563-70. PubMed ID: 15608669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.
    Pantuck AJ; An J; Liu H; Rettig MB
    Cancer Res; 2010 Jan; 70(2):752-61. PubMed ID: 20068166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
    Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
    Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy.
    Sourbier C; Danilin S; Lindner V; Steger J; Rothhut S; Meyer N; Jacqmin D; Helwig JJ; Lang H; Massfelder T
    Cancer Res; 2007 Dec; 67(24):11668-76. PubMed ID: 18089796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma.
    Morais C; Gobe G; Johnson DW; Healy H
    Apoptosis; 2010 Apr; 15(4):412-25. PubMed ID: 19856104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
    Yuen JS; Akkaya E; Wang Y; Takiguchi M; Peak S; Sullivan M; Protheroe AS; Macaulay VM
    Mol Cancer Ther; 2009 Jun; 8(6):1448-59. PubMed ID: 19509240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of nuclear factor kappa B attenuates tumour progression in an animal model of renal cell carcinoma.
    Morais C; Healy H; Johnson DW; Gobe G
    Nephrol Dial Transplant; 2010 May; 25(5):1462-74. PubMed ID: 20037166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.
    An J; Rettig MB
    Mol Cell Biol; 2005 Sep; 25(17):7546-56. PubMed ID: 16107702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells.
    Malec V; Coulson JM; Urbé S; Clague MJ
    J Proteome Res; 2015 Dec; 14(12):5263-72. PubMed ID: 26506913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway.
    Ch'ng WC; Abd-Aziz N; Ong MH; Stanbridge EJ; Shafee N
    Cell Oncol (Dordr); 2015 Aug; 38(4):279-88. PubMed ID: 25930675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice.
    Wang J; Ma Y; Jiang H; Zhu H; Liu L; Sun B; Pan S; Krissansen GW; Sun X
    J Hepatol; 2011 Aug; 55(2):359-68. PubMed ID: 21168458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
    Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST
    PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
    Sim MY; Huynh H; Go ML; Yuen JSP
    PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms.
    Calzada MJ; Esteban MA; Feijoo-Cuaresma M; Castellanos MC; Naranjo-Suárez S; Temes E; Méndez F; Yánez-Mo M; Ohh M; Landázuri MO
    Cancer Res; 2006 Feb; 66(3):1553-60. PubMed ID: 16452212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.
    Yi Y; Mikhaylova O; Mamedova A; Bastola P; Biesiada J; Alshaikh E; Levin L; Sheridan RM; Meller J; Czyzyk-Krzeska MF
    Clin Cancer Res; 2010 Nov; 16(21):5142-52. PubMed ID: 20978146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular biology of renal cell cancer and the identification of therapeutic targets.
    Iliopoulos O
    J Clin Oncol; 2006 Dec; 24(35):5593-600. PubMed ID: 17158545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.